A Study of ARRY-380 in Patients With Advanced HER2+ Cancer

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 10 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tucatinib (Primary)
Indications Advanced breast cancer; Bladder cancer; Colorectal cancer; Endometrial cancer; Lung cancer; Ovarian cancer; Prostate cancer; Salivary gland cancer; Solid tumours
Focus Adverse reactions; Biomarker; Pharmacogenomic; Pharmacokinetics
Sponsors Seagen; Seattle Genetics

04 Jan 2017 Results analysing maximum tolerated dose(MTD), pharmacokinetics and antitumor activity published in the Clinical cancer research: an official journal of the American Association for Cancer Research.
07 Oct 2013 Final results will be presented at the American Association for Cancer Research Special Conference on Advances in Breast Cancer Research according to an Oncothyreon media release. Results were also reported in the media release.
30 May 2013 Results reported in an Oncothyreon and Array BioPharma media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com